Immunotherapy trial for advanced colorectal cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that cannot be removed with surgery or has spread to other parts of the body.
- You have not had chemotherapy for metastatic disease before, and at least 6 months have passed since any prior chemotherapy after surgery.
- You have a tumor that can be measured on scans, and you are willing to have biopsies (tissue samples) before and during treatment if safe.
- You are in good overall health (able to care for yourself) and your life expectancy is more than 3 months.
- You do not have certain autoimmune diseases, a BRAF mutation, or other conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.